CCP–DRAP MoU Aims to Curb Misleading Ads, Ensure Fair Competition in Pharma Sector -

PAKISTAN

The Competition Commission of Pakistan (CCP) and the Drug Regulatory Authority of Pakistan (DRAP) have signed a Memorandum of Understanding (MoU) designed to strengthen regulatory oversight, curb misleading advertisements, and promote fair competition within the pharmaceutical and healthcare products market.

According to the agreement, the MoU aims to enhance information and data exchange, enable joint enforcement actions, and support monitoring of deceptive advertising practices, particularly in over-the-counter (OTC) categories. The framework also targets unfair competition, unsubstantiated medical claims, and promotional tactics that may mislead consumers or compromise public health.

In addition, the cooperation model includes digital data sharing, institutional capacity building, and collaborative research and policy analysis, allowing both agencies to develop more effective regulatory responses in an evolving marketplace.

Speaking at the signing ceremony, CCP Member Salman Amin said the partnership will play a critical role in protecting consumers, especially at a time when online advertising and e-commerce have amplified misleading marketing trends. He stressed that the pharmaceutical sector has a direct bearing on public health, making inter-agency coordination essential for ensuring transparency and competitive fairness.

DRAP Chief Executive Dr. Ubaidullah highlighted that while both CCP and DRAP operate under distinct legal mandates, their core objectives—consumer protection, market stability, and fair competition—remain aligned. He noted that even after the deregulation of drug prices, continued vigilance is required to ensure pharmaceutical companies follow market principles and maintain adequate supply levels.

He added that enhanced coordination will improve regulatory outcomes, ensuring the availability, affordability, and fair pricing of essential medicines, while strengthening public confidence in the healthcare products market.

The MoU is expected to set a new benchmark for collaborative regulation in Pakistan’s pharmaceutical sector, promoting transparency, accountability, and consumer welfare. – ERMD

READ MORE